Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 0%
Hold 82%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a well-positioned global life science tools company with a strong presence in the US (55% of revenue) and Europe, Middle East, and Africa (20%) markets. The company's sales have been impacted by some adverse timing in the cell therapy segment, but this is expected to improve in the future. The company has a solid portfolio of products and a transformative acquisition of Wilson Wolf, a leader in cell therapy manufacturing, which is not yet fully appreciated by investors.

Bears say

Bio-Techne is facing numerous risks in the near future, including end-market recovery delays, potential share loss to competitors, challenges in the progress of cell therapy development, and risks associated with company acquisitions. Additionally, there is the potential for market share to be lost to companies that have been acquired by larger competitors. While Bio-Techne shows commitment to sustainability practices, there is not currently a direct link between these practices and executive compensation, which could create potential risks for the company's long-term performance and growth. Overall, these factors contribute to our negative outlook on Bio-Techne's stock.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 0% recommend Buy, 82% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.